| abstract |
The invention concerns the use of a protein derived from cancer cells, virus-infected cells or immune-defence cells or a fragment of said protein, characterised in that said protein is initially an immunosuppressive and/or angiogenic protein with local activity and said properties are inactivated by at least 70 %, through a physical and/or chemical treatment, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed against said protein, and preserving sufficient immunogenic properties for generating antibodies neutralizing or blocking said native protein, to obtain a medicine for use as local anti-immnumosuppression and/or anti-angiogenic agent as an anticancer agent. The invention also concerns the resulting immunogenic compounds, their preparation method and their uses. |